By Chris Wack

 

VectivBio Holding AG said the U.S. Food and Drug Administration has cleared its Investigational New Drug application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial for the treatment of steroid-refractory acute graft-versus-host disease.

Apraglutide previously received orphan drug designation by the FDA for the prevention of aGVHD in June.

The biopharmaceutical company said it plans to start dosing the first patient in a Phase 2 clinical trial in the first quarter of 2022.

The Phase 2 study will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Interim data read out is anticipated for the second half of 2022.

VectivBio shares were up 2%, to $6.48, in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 20, 2021 07:39 ET (11:39 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
VectivBio (NASDAQ:VECT)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more VectivBio Charts.
VectivBio (NASDAQ:VECT)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more VectivBio Charts.